2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow Myelodysplastic Disorders: new trials by email Literature Review of Myelodysplastic Disorders trials Research Report on Myelodysplastic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Idarubicin, Sorafenib, Ara-C - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 78 | 2007-10-01 | 2018-08-23 |
| Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H FLUDARABINE, CAMPATH 1H, FK50 - Myelodysplastic Disorders, Leukemia | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 40 | 2000-06-01 | 2020-01-18 |
Leukemia (2) · Leukemia, Myeloid, Acute (1) · Lymphoproliferative Disorders (1) · Multiple Myeloma (1) · Paraproteinemias (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Neoplasms, Plasma Cell (1) · Vascular Diseases (1)
Alemtuzumab (1) · Cytarabine (1) · Idarubicin (1) · Sorafenib (1) · fludarabine (1)
Baylor College of Medicine (1) · M.D. Anderson Cancer Center (1)
United States (2)
Farhad Ravandi-Kashani, MD (1) · George Carrum, MD (1)